R Basuroy1, A Haji1, J K Ramage1,2, A Quaglia3, R Srirajaskanthan1,4. 1. ENETS Neuroendocrine Centre of Excellence, Institute of Liver studies, Kings College Hospital, London, UK. 2. Gastroenterology Department, Hampshire Hospitals NHS Trust, Hampshire, UK. 3. Histopathology Department, ENETS Neuroendocrine Centre of Excellence, Institute of Liver studies, Kings College Hospital, London, UK. 4. Gastroenterology Department, University Hospital Lewisham, London, UK.
Abstract
BACKGROUND: Rectal neuroendocrine tumours (NETs) are increasingly identified at endoscopy possibly as a result of bowel cancer screening programmes. AIM: To present a review of the literature to aid clinicians in the diagnosis and management of rectal neuroendocrine tumours. METHODS: A literature search was conducted through MEDLINE using search terms: rectal, rectum, carcinoid, NET, therapy, endoscopy, mucosal resection, submucosal dissection. Relevant articles were identified through manual review with reference lists reviewed for additional articles. RESULTS: The incidence of rectal neuroendocrine tumours is approximately 1 per 100 000 population per year with the majority (80-90%) being <1 cm and localised to the submucosa. Metastatic disease is infrequent (<20%) with risk factors including size, atypical appearance, grade and depth of invasion. The primary resection modality influences complete resection rates and the need for secondary therapy. A thorough pre-resection diagnostic work up is required for lesions that are at higher risk of invasion and metastasis. Device-assisted endoscopic mucosal resection and endoscopic submucosal dissection are used to resect localised rectal neuroendocrine tumours <2 cm. Transanal surgery is also used to resect localised 1-2 cm rectal neuroendocrine tumours. Oncological surgical resection is used for rectal neuroendocrine tumours that are >2 cm or with invasion and regional disease. The treatment of advanced disease is multimodal. CONCLUSIONS: The long-term tumour biology of small rectal neuroendocrine tumours remains unclear. There is uncertain impact from bowel cancer screening programmes on rectal neuroendocrine tumour incidence, morbidity and mortality. Referral to neuroendocrine tumour centres for patients with locally advanced disease or metastatic disease is recommended.
BACKGROUND:Rectal neuroendocrine tumours (NETs) are increasingly identified at endoscopy possibly as a result of bowel cancer screening programmes. AIM: To present a review of the literature to aid clinicians in the diagnosis and management of rectal neuroendocrine tumours. METHODS: A literature search was conducted through MEDLINE using search terms: rectal, rectum, carcinoid, NET, therapy, endoscopy, mucosal resection, submucosal dissection. Relevant articles were identified through manual review with reference lists reviewed for additional articles. RESULTS: The incidence of rectal neuroendocrine tumours is approximately 1 per 100 000 population per year with the majority (80-90%) being <1 cm and localised to the submucosa. Metastatic disease is infrequent (<20%) with risk factors including size, atypical appearance, grade and depth of invasion. The primary resection modality influences complete resection rates and the need for secondary therapy. A thorough pre-resection diagnostic work up is required for lesions that are at higher risk of invasion and metastasis. Device-assisted endoscopic mucosal resection and endoscopic submucosal dissection are used to resect localised rectal neuroendocrine tumours <2 cm. Transanal surgery is also used to resect localised 1-2 cm rectal neuroendocrine tumours. Oncological surgical resection is used for rectal neuroendocrine tumours that are >2 cm or with invasion and regional disease. The treatment of advanced disease is multimodal. CONCLUSIONS: The long-term tumour biology of small rectal neuroendocrine tumours remains unclear. There is uncertain impact from bowel cancer screening programmes on rectal neuroendocrine tumour incidence, morbidity and mortality. Referral to neuroendocrine tumour centres for patients with locally advanced disease or metastatic disease is recommended.
Authors: Trilokesh D Kidambi; Christina Pedley; Amie Blanco; Emily K Bergsland; Jonathan P Terdiman Journal: Fam Cancer Date: 2017-10 Impact factor: 2.375
Authors: Juliana Silveira Lima de Castro; Evandra Cristina Vieira da Rocha; Vanessa Assis do Vale; Paula Mendonça; Oswaldo Wiliam Marques; Eloy Taglieri; Francisco Susumu Correa Koyama; Celso Augusto Milani Cardoso Filho; Wilson Toshihiko Nakagawa Journal: Turk J Gastroenterol Date: 2021-08 Impact factor: 1.852